[EN] SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS CYCLIQUES SUBSTITUÉS ET PROCÉDÉS D'UTILISATION
申请人:XI NING
公开号:WO2013138210A1
公开(公告)日:2013-09-19
The present invention provides novel substituted cyclic compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
[EN] OXABOROLE ESTERS AND USES THEREOF<br/>[FR] ESTERS D'OXABOROLE ET LEURS UTILISATIONS
申请人:ANACOR PHARMACEUTICALS INC
公开号:WO2017195069A1
公开(公告)日:2017-11-16
The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.
APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
申请人:Bruncko Milan
公开号:US20100305122A1
公开(公告)日:2010-12-02
Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES
申请人:Merck Patent GmbH
公开号:US20160168090A1
公开(公告)日:2016-06-16
The present invention relates to indole compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.
本发明涉及吲哚化合物及其药用可接受的组合物,用作P2X7拮抗剂,用于治疗与P2X7相关的疾病。
[EN] N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS<br/>[FR] N-(PHÉNYLSULFONYL) BENZAMIDES ET COMPOSÉS APPARENTÉS EN TANT QU'INHIBITEURS DE BCL-2
申请人:UNIV MICHIGAN REGENTS
公开号:WO2018027097A1
公开(公告)日:2018-02-08
The present disclosure provides compounds having Formula I-A: and the pharmaceutically acceptable salts and solvates thereof, wherein A, X1 , X2, X3 R1a, R1b E, and = are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a disease, disorder, or condition responsive to Bc1-2 protein inhibition such as cancer.